Sofinnova Partners and Polaris Partners have co-led a CHF 54m series-A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders.
Sofinnova, Polaris lead CHF 54m series-A for Noema
Most Popular
Sofinnova Partners and Polaris Partners have co-led a CHF 54m series-A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders.